Entrepreneur. Drug hunter. Anti-ideologues, Anti-medical nihilists, Optimist My NGO: https://xitter.cf/t.co/yDWRnOYAyY https://xitter.cf/t.co/SOf8c5OZm6
Joined December 2009
- Tweets37.8K
- Following5.5K
- Followers11.6K
- Likes42.8K
Pinned Tweet
I think Dr. Kurzrock is making a very important point that some people are missing. I asked Claude to create an illustration of what I mean.
For a given cancer, the incidence is relatively fixed, which means the clinical trial patient pool is relatively fixed.
Same pool of patients buys you 24 small ORR trials or 2 big crossover OS trials. Also, a big crossover OS RCT DOES NOT guarantee to give you a BETTER drug - which is the point @Dr_R_Kurzrock is making.
Over lets say 15 years, as a PUBLIC POLICY, what regulatory approval standards will give you the GREATEST IMPROVEMENT IN CANCER CARE?
This is completely DIFFERENT from the question: "which trial design will give you the most ACCURATE assessment of an individual drug's efficacy?"
I also understand the argument that patients will end up paying for drugs that may not work better than SOC. Sure, this may be true at any given snapshot in time, but it is UNLIKELY TO BE TRUE over 24 iterations across 15 years.
Also. I don't buy the argument that you save society money, as the # of patients treated is also relatively fixed. The same $$$ will be spent on the older SOC.
Heading to Jefferies London for the first time next month.
What are the hottest receptions to attend? :) DM please! 🙏😃
Followed for the name alone!
Hard Drugs now has a twitter account!
Follow us here @harddrugspod to hear about new episodes and behind-the-scenes goofs.
Poll for biotech entrepreneurs and biotech/pharma BD folks:
What do you use for your fundraising or BD tracker?
I personally use excel, which I kind of hate.
If you use software or SaaS, please reply with the name. Thanks!
49%Excel or Google Sheets
16%Software or SaaS app
35%Show me the answers
43 votes • 21 hours Jing Liang 🇺🇦 retweeted
CIRM is actually a pretty good example of how NOT to do it. Most $ went to pure research labs (incestuous w deciders) and Stem cell stuff (gen pretty scammy). Very little was true VC that resulted in drugs.
Not unexpected given impetus of CIRM was political outrage mongering.
Jing Liang 🇺🇦 retweeted
Today, we’re announcing an open call for guest investigators in life sciences. Over 8–12 weeks, guest investigators will work directly with my team and other Anthropic researchers to produce analyses and tools for their work. We’ll run our models and harnesses, at no cost to them. We’ll work together to open-source the resulting data, artifacts, and code, and write preprints about what we find.
We want humans to remain at the center of scientific discovery, deciding what questions to pursue, and how to pursue them. Those decisions are not ours to make alone. This open call is part of our ongoing efforts at Anthropic to support researchers and accelerate scientific discovery.
I’m looking for principal investigators and their research groups at academic institutions, nonprofits, or government labs, working in causal human biology, structural and computational molecular biology, medicinal chemistry, drug discovery, and clinical science.
Applications are open for about 14 days: anthropic.com/news/open-call…
Jing Liang 🇺🇦 retweeted
Which part of this do you object to? The hearing protection? The eye protection? The body armor? Or gene edits that makes them less likely to develop cancer and joint problems?
There is a reason the American Humane Society is supporting this.
Jing Liang 🇺🇦 retweeted
At @OpenAI we are hiring a Life Sciences Partnerships Lead to shape and execute OpenAI’s global life sciences partnership strategy. You will lead high-impact research, product, and platform partnerships across the life sciences ecosystem. Learn more and apply at
openai.com/careers/business-…
One of the most contentious point about this proposal is whether adding blanket biotech is authorized under the COINS Act.
"The Treasury Secretary can add other categories that enable military, intelligence, surveillance, or cyber-enabled capabilities..."
How would lets say antibodies or potential cures for human disease qualify under that clause.
Feels like bad sci-fi movies becoming reality..
Warhound, the brain child of Ben Lamm and Palmer Luckey, emerges from stealth to genetically engineer dogs for military and law enforcement.
spr.ly/6011BHZNMF
Not the only reason. Chinese VCs invest in very early stage companies. Where as many US VCs will not look at a company until it is at DC or Ph 1, Chinese VCs will write small checks to founders with just an idea.
China has gotten ahead of the US in biotechnology, largely by making their clinical trial system more effective. I covered this in a @nytimes article.
Now, American patients are travelling there to have access to drugs they can't access at home. It's high time the US woke up and implemented much needed reforms.
Jing Liang 🇺🇦 retweeted
Retatrutide and the improvement of obstructive sleep apnea nejm.org/doi/full/10.1056/NE…
Jing Liang 🇺🇦 retweeted
I injected the HBV genome in mice & dosed them with an early version of ASO drug against the HBV RNA that eventually 10 years later is now an FDA approved therapy! A side project, I was able to see efficient knockdown back then.
pubmed.ncbi.nlm.nih.gov/2665…
ir.ionis.com/news-releases/n…
Jing Liang 🇺🇦 retweeted
A watershed for FDA regulation. Every patient on the vaccine arm got a different product, with neoantigens chosen from sequencing of each person's own tumor. So FDA had no single active sequence to review. The IND pre-specified how the product would change for each patient.
#ESMO26 embargo lifted following breach.
Detailed data confirm Moderna $MRNA and Merck $MRK cancer vaccine met key endpoints in melanoma trial
Personalized mRNA therapy reduced disease recurrence by 42% compared to standard treatment
statnews.com/2026/10/22/esmo…
Jing Liang 🇺🇦 retweeted
When I was investing in healthcare in the early 2000s, the US was an incredible force in biotech and China was known for just making raw materials. Wow, the world has flipped. It’s remarkable how China has become a powerhouse in drug discovery and is now leading. The world will shift again with AI, but the country that wins will be the ones that have large data initiatives to fuel discovery and a nimble regulatory oversight to partner and not hinder progress.
In January 2025 my mom’s lung cancer spread to her brain. The drug with the best chance of helping her was approved in China but not here.
A doctor told me, almost as an aside, that if she were Chinese she could buy it at a pharmacy.
So I flew to Shanghai and came home with 26 boxes in my luggage. That was 19 months ago. My mom is still here, still working, and in her words has had an amazing three years.
The drug was approved in China in 2023. The FDA approved it in July 2025. It still is not for sale here. I know of at least 30 Americans who have made the same trip.
I have been scared to tell this story because I worried it could cost my mom access to the medicine keeping her alive. But the problem matters more than my silence. These drugs need to be developed and available here, and that means FDA reform.
Art Allen at KFF Health News told our story this week. It also ran in The Washington Post.
kffhealthnews.org/health-ind…
Jing Liang 🇺🇦 retweeted
“Your shops that got looted were nice, okay, but we’re starving.”
People looked this girl up and her dad is a corporate executive who worked for Shell.
What a smug psychopath.
Jing Liang 🇺🇦 retweeted
The GRU hacked into Jared Kushner's iPhone. Dutch military intelligence (MIVD) then recruited a GRU spy who gave them access to the hacked phone. What MIVD discovered was that Kushner had access to two bank accounts --one Azerbaijani, the other Israeli --where Saudi Crown Prince Mohammed bin Salman and Emirati ruler Mohammed bin Zayed deposited money. It sounds like a slightly far-fetched episode of "Slow Horses," but it's real. And it proves just how eye-poppingly corrupt this administration was and continues to be as its "special envoy" decides the fate of tens of millions in Europe in the Middle East. Simply incredible reporting by Matthew Cole, drawn from his new book on Kushner. vanityfair.com/story/jared-k…
